Although discontinuation of nucleos (t) ide analogue (NA) treatment before HBsAg loss is
part of all current HBV treatment guidelines for HBeAg-positive patients who achieve HBeAg …

Background and Aims Cancer‐associated fibroblasts (CAFs) are key players in multicellular,
stromal‐dependent alterations leading to HCC pathogenesis. However, the intricate …

Background & Aim Antiviral therapy has greatly improved the outcomes of patients with
chronic hepatitis B virus (HBV) infection and active liver disease or advanced …

Chronic hepatitis B virus (HBV) infection is currently incurable. Long-term treatment with
potent and safe nucleos (t) ide analogs (NAs) can reduce hepatocellular carcinoma (HCC) …

Chronic hepatitis B (CHB) infection is rarely eradicated by current antiviral nucleos (t) ide
analogues. We found that α2, 6-biantennary sialoglycans of HBV surface antigen (HBsAg) …

Background Intestinal flora plays a critical role in immunity against hepatitis B virus (HBV).
Fecal Microbiota Transplantation (FMT) may be a potential immunomodulatory therapy in …

Nucleoside and nucleotide analogues are essential antivirals in the treatment of infectious
diseases such as human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C …

Methods Among 125 untreated patients that were hepatitis B e-antigen positive, hepatitis B
virus-DNA> 20,000 IU/mL, with normal alanine aminotransferase level from 2012 to 2018 …

Background Tenofovir amibufenamide (TMF) can provide more efficient delivery than
tenofovir disoproxil fumarate (TDF). Aim To compare the efficacy and safety of TMF and TDF …

Nucleos (t) ide analogues with high barrier to resistance are regarded as the principal
therapeutic option for chronic hepatitis B (CHB). Treatment with entecavir (ETV), tenofovir …